BACKGROUND: ABT-751 is a novel antimitotic agent that exerted cytotoxic effects in preclinical studies. Carboplatin has efficacy in treating advanced non-small cell lung cancer (NSCLC) in combination with other drugs. METHODS: Lung cancer cell lines were treated with ABT-751 and/or carboplatin to investigate their impact on cell growth. A phase I study with an expansion cohort was conducted in previously treated NSCLC patients. The primary objective was the maximum tolerated dose (MTD); secondary objectives were objective response rates, median survival, time to tumor progression, dose-limiting toxicities (DLTs), and pharmacodynamic evaluation of buccal swabs. RESULTS: Combining ABT-751 with carboplatin significantly reduced growth and induced apoptosis of lung cancer cell lines. Twenty advanced NSCLC patients were enrolled. MTD was ABT-751 125 mg orally twice daily for 7 days with carboplatin AUC 6. DLTs included fatigue, ileus, neutropenia and pneumonitis. Two patients had confirmed partial responses. Median overall survival was 11.7 months (95% CI 5.9-27.0). Time to tumor progression was 2.8 months (95% CI 2.0-2.7). Four of 6 patients showed decreased cyclin D1 protein in posttreatment versus pretreatment buccal swabs. CONCLUSION: Combining ABT-751 with carboplatin suppressed growth of lung cancer cell lines and had modest clinical antitumor activity in advanced NSCLC previously treated predominantly with carboplatin. Further studies of this combination are not recommended while investigations of biomarkers in different patient populations, alternative schedules and combinations may be pursued.
BACKGROUND:ABT-751 is a novel antimitotic agent that exerted cytotoxic effects in preclinical studies. Carboplatin has efficacy in treating advanced non-small cell lung cancer (NSCLC) in combination with other drugs. METHODS:Lung cancer cell lines were treated with ABT-751 and/or carboplatin to investigate their impact on cell growth. A phase I study with an expansion cohort was conducted in previously treated NSCLCpatients. The primary objective was the maximum tolerated dose (MTD); secondary objectives were objective response rates, median survival, time to tumor progression, dose-limiting toxicities (DLTs), and pharmacodynamic evaluation of buccal swabs. RESULTS: Combining ABT-751 with carboplatin significantly reduced growth and induced apoptosis of lung cancer cell lines. Twenty advanced NSCLCpatients were enrolled. MTD was ABT-751 125 mg orally twice daily for 7 days with carboplatin AUC 6. DLTs included fatigue, ileus, neutropenia and pneumonitis. Two patients had confirmed partial responses. Median overall survival was 11.7 months (95% CI 5.9-27.0). Time to tumor progression was 2.8 months (95% CI 2.0-2.7). Four of 6 patients showed decreased cyclin D1 protein in posttreatment versus pretreatment buccal swabs. CONCLUSION: Combining ABT-751 with carboplatin suppressed growth of lung cancer cell lines and had modest clinical antitumor activity in advanced NSCLC previously treated predominantly with carboplatin. Further studies of this combination are not recommended while investigations of biomarkers in different patient populations, alternative schedules and combinations may be pursued.
Authors: Konstantin H Dragnev; Tian Ma; Jobin Cyrus; Fabrizio Galimberti; Vincent Memoli; Alexander M Busch; Gregory J Tsongalis; Marc Seltzer; David Johnstone; Cherie P Erkmen; William Nugent; James R Rigas; Xi Liu; Sarah J Freemantle; Jonathan M Kurie; Samuel Waxman; Ethan Dmitrovsky Journal: Cancer Prev Res (Phila) Date: 2011-06
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Charles M Rudin; Ann Mauer; Martin Smakal; Rosalyn Juergens; Stanislav Spelda; Michael Wertheim; Andrew Coates; Evelyn McKeegan; Peter Ansell; Xiangdong Zhou; Jane Qian; Rajendra Pradhan; Barry Dowell; Andrew Krivoshik; Gary Gordon Journal: J Clin Oncol Date: 2011-02-07 Impact factor: 44.544
Authors: Yanping Luo; Vincent P Hradil; David J Frost; Saul H Rosenberg; Gary B Gordon; Sherry J Morgan; Gerard D Gagne; Bryan F Cox; Stephen K Tahir; Gerard B Fox Journal: Anticancer Drugs Date: 2009-07 Impact factor: 2.248
Authors: J Michels; S L Ellard; L Le; C Kollmannsberger; N Murray; E S Tomlinson Guns; R Carr; K N Chi Journal: Ann Oncol Date: 2009-07-24 Impact factor: 32.976
Authors: Ann M Mauer; Ezra E W Cohen; Patrick C Ma; Mark F Kozloff; Lee Schwartzberg; Andrew I Coates; Jiang Qian; Anne E Hagey; Gary B Gordon Journal: J Thorac Oncol Date: 2008-06 Impact factor: 15.609
Authors: Christopher G Azzoli; Sherman Baker; Sarah Temin; William Pao; Timothy Aliff; Julie Brahmer; David H Johnson; Janessa L Laskin; Gregory Masters; Daniel Milton; Luke Nordquist; David G Pfister; Steven Piantadosi; Joan H Schiller; Reily Smith; Thomas J Smith; John R Strawn; David Trent; Giuseppe Giaccone Journal: J Clin Oncol Date: 2009-11-16 Impact factor: 44.544
Authors: Edward S Kim; Vera Hirsh; Tony Mok; Mark A Socinski; Radj Gervais; Yi-Long Wu; Long-Yun Li; Claire L Watkins; Mark V Sellers; Elizabeth S Lowe; Yan Sun; Mei-Lin Liao; Kell Osterlind; Martin Reck; Alison A Armour; Frances A Shepherd; Scott M Lippman; Jean-Yves Douillard Journal: Lancet Date: 2008-11-22 Impact factor: 79.321
Authors: Mostafa M Ghorab; Mansour S Alsaid; Mohamed S A El-Gaby; Mahmoud M Elaasser; Yassin M Nissan Journal: Chem Cent J Date: 2017-04-07 Impact factor: 4.215
Authors: Tian Ma; Alexandra G N Lopez-Aguiar; Aihua Li; Yun Lu; David Sekula; Eugene E Nattie; Sarah Freemantle; Ethan Dmitrovsky Journal: Cancer Biol Ther Date: 2014-02-20 Impact factor: 4.742
Authors: Xin Zhang; Sudhir Raghavan; Michael Ihnat; Jessica E Thorpe; Bryan C Disch; Anja Bastian; Lora C Bailey-Downs; Nicholas F Dybdal-Hargreaves; Cristina C Rohena; Ernest Hamel; Susan L Mooberry; Aleem Gangjee Journal: Bioorg Med Chem Date: 2014-05-14 Impact factor: 3.641
Authors: Lawrence Nnamdi Obasi; Uchechukwu Susan Oruma; Ibrahim Abdulrazak Al-Swaidan; Ponnadurai Ramasami; Chigozie Julius Ezeorah; Alfred Ezinna Ochonogor Journal: Molecules Date: 2017-02-22 Impact factor: 4.411